WILMINGTON, Mass., March 27, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
today announced the appointment of Jonathan
Saunders into the newly created position of Manufacturing
Manager. Mr. Saunders will report to Brenda
Baron, Vice President of Manufacturing Operations.
"In fiscal 2013, we shipped more ETDs than in any other year in
our Company's history, a trend we expect will continue. We believe
that the regulatory approvals we've recently received will prove to
be key drivers of growth. Having moved into our new 58,000 square
foot state-of-the-art manufacturing facility last summer, we now
have the capacity to produce the quantities necessary to meet our
expected future demand," stated Implant Sciences' Chief Operating
Officer, Dr. Bill McGann. "Jon
is an important hire for our company to support this rapid growth
in manufacturing."
"We welcome Jon, who has a strong track record of managing
high-tech manufacturing for companies with rapid revenue and
production growth. We believe that his experience will be valuable
in his position as Manufacturing Manager. As the only
American-owned ETD manufacturer to have product qualification from
the TSA, we are proud of our commitment to manufacture in the
USA," added Brenda Baron, Vice President of Manufacturing
Operations.
Mr. Saunders' expertise is in managing growing manufacturing
operations with a focus on driving efficiency and profitability. He
was most recently Plant Manager at EIT Northeast Operations, a
manufacturer of printed circuit board assemblies (PCBAs) and
complex system assemblies, where he managed a 40% revenue increase.
Prior, he served for ten years in several positions with
Sanmina-SCI, a global contract manufacturer of top level electronic
assemblies. He was Vice President of Operations at Sanmina-SCI's
Woburn, Massachusetts plant, and
Plant Manager of the company's Manchester, New Hampshire facility, where he
oversaw a significant increase in revenues as well as increased
labor efficiencies. Mr. Saunders has also served as Plant Manager
for Mack Technologies, Operations Manager for Bull Electronics, and
Manufacturing Manager for Teledyne Electro-Mechanisms.
About Implant Sciences
Implant Sciences is the leader in next generation
Explosives Trace Detection (ETD) technology. In January 2013,
the Company became only the third ETD manufacturer, and the sole
American-owned company, to have product approval from the US
Transportation Security Administration. Implant Sciences has
developed proprietary technologies used in its commercial
explosives and drugs trace detection systems, which ship to a
growing number of locations domestically and
internationally. Implant Sciences' QS-H150 portable
explosives trace detector has received Qualified Anti-Terrorism
Technology Designation and, in addition to receiving TSA
qualification for air cargo screening, the Company's QS-B220 has
also received STAC certification, a Developmental Testing &
Evaluation (DT&E) Designation by the U.S. Department of
Homeland Security under the Support Anti-terrorism by
Fostering Effective Technology Act of 2002 (the SAFETY Act),
and the GSN 2013 Homeland Security Award for "Best Explosives
Detection Solution". For further details on the Company and its
products, please visit the Company's website
at http://www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
our explosives detection products and technologies (including any
new products we may develop) may not be accepted by the
Transportation Security Administration or by other U.S. or foreign
government and law enforcement agencies or commercial consumers of
security products; economic, political and other risks associated
with international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
lmoody@corporateprofile.com
SOURCE Implant Sciences Corporation